Subsequent retrospective analyses also proposed that CDK4/6 inhibitors combined with endocrine therapy may not show reduced efficacy in all HR+/HER2-low breast cancer cases, and it is likely that HER2 expression may be a contributing factor20–22. This evidence concerns the gene ERBB2 and breast carcinoma.